[go: up one dir, main page]

MX2016004540A - Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda). - Google Patents

Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).

Info

Publication number
MX2016004540A
MX2016004540A MX2016004540A MX2016004540A MX2016004540A MX 2016004540 A MX2016004540 A MX 2016004540A MX 2016004540 A MX2016004540 A MX 2016004540A MX 2016004540 A MX2016004540 A MX 2016004540A MX 2016004540 A MX2016004540 A MX 2016004540A
Authority
MX
Mexico
Prior art keywords
receptor activity
nmda receptor
thiazolopyrimidinones
modulators
compounds
Prior art date
Application number
MX2016004540A
Other languages
English (en)
Inventor
Po-Wai Yuen
Cuong Ly
Guosheng Wu
Jiang Yu
Elisia Villemure
Jacob Schwarz
Benjamin Sellers
Matthew Volgraf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016004540A publication Critical patent/MX2016004540A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a ciertos compuestos de tiazolopirimidinona, a composiciones farmacéuticas que contienen tales compuestos y a métodos de tratamiento empleando los compuestos.
MX2016004540A 2013-10-11 2014-10-08 Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda). MX2016004540A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013085031 2013-10-11
CN2014085959 2014-09-05
PCT/EP2014/071522 WO2015052226A1 (en) 2013-10-11 2014-10-08 Thiazolopyrimidinones as modulators of nmda receptor activity

Publications (1)

Publication Number Publication Date
MX2016004540A true MX2016004540A (es) 2016-07-21

Family

ID=51688060

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004540A MX2016004540A (es) 2013-10-11 2014-10-08 Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).

Country Status (19)

Country Link
US (2) US9988400B2 (es)
EP (2) EP3415519A1 (es)
JP (2) JP6419800B2 (es)
KR (1) KR102361108B1 (es)
CN (2) CN105612162B (es)
BR (1) BR112016007563B1 (es)
CA (1) CA2926830C (es)
DK (1) DK3055315T3 (es)
ES (1) ES2690355T3 (es)
HR (1) HRP20181596T1 (es)
HU (1) HUE040651T2 (es)
LT (1) LT3055315T (es)
MX (1) MX2016004540A (es)
PL (1) PL3055315T3 (es)
PT (1) PT3055315T (es)
RS (1) RS58047B1 (es)
RU (1) RU2703273C2 (es)
SI (1) SI3055315T1 (es)
WO (1) WO2015052226A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170462A (es) 2015-04-15 2018-02-01 Hoffmann La Roche Piridopirimidinonas y utilización de las mismas como moduladores de receptores nmda
ES2950348T3 (es) 2015-12-09 2023-10-09 Novartis Ag Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos
LT3386591T (lt) 2015-12-09 2020-10-12 Cadent Therapeutics, Inc. Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas
WO2017109709A2 (en) 2015-12-22 2017-06-29 Novartis Ag A high-throughput assay method for identifying allosteric nmda receptor modulators
ES2975336T3 (es) 2016-12-22 2024-07-04 Novartis Ag Moduladores del receptor NMDA y usos de los mismos
ES2951872T3 (es) 2018-08-03 2023-10-25 Novartis Ag Moduladores del receptor NMDA heteroaromáticos y usos de los mismos
CN111840296B (zh) * 2020-07-22 2021-05-04 华中农业大学 一种5H-噻唑并[3,2-a]嘧啶-5-酮类化合物在制备单胺氧化酶抑制剂中的用途
CN112094267B (zh) * 2020-08-14 2025-06-06 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 1-苯基-吡咯并异喹啉-3-酮类化合物及其制备方法和应用
EP4032896A1 (en) * 2021-01-20 2022-07-27 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof
CN112724157B (zh) * 2021-01-23 2022-04-19 中国科学院新疆理化技术研究所 二氢噁唑并[5,4-d]吡咯并[1,2-a]嘧啶-9(5H)-酮类衍生物及用途
WO2023009836A1 (en) * 2021-07-30 2023-02-02 The Regents Of The University Of California Slc26a3 inhibitors and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888983A (en) * 1970-08-14 1975-06-10 Seperic Derivatives of thiazolino-pyrimidin-6-ones, in inducing analgesia
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
ATE214704T1 (de) * 1997-07-18 2002-04-15 Hoffmann La Roche 5h-thiazolo(3,2-a)pyrimidinderivate
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2007006175A1 (en) 2005-07-11 2007-01-18 Zte Corporation Method for implementing channel shared ring protection supported easy failure prevention
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
CN105308039B (zh) 2013-06-19 2019-06-28 豪夫迈·罗氏有限公司 吲哚满-2-酮或吡咯并-吡啶/嘧啶-2-酮衍生物
CR20170462A (es) 2015-04-15 2018-02-01 Hoffmann La Roche Piridopirimidinonas y utilización de las mismas como moduladores de receptores nmda

Also Published As

Publication number Publication date
DK3055315T3 (en) 2018-10-22
US10647731B2 (en) 2020-05-12
US20160222033A1 (en) 2016-08-04
CA2926830A1 (en) 2015-04-16
BR112016007563A2 (pt) 2020-04-28
BR112016007563B1 (pt) 2022-12-20
US20180244694A1 (en) 2018-08-30
US9988400B2 (en) 2018-06-05
HUE040651T2 (hu) 2019-03-28
PT3055315T (pt) 2018-10-25
CN105612162A (zh) 2016-05-25
RU2016115487A3 (es) 2018-06-21
JP2016532669A (ja) 2016-10-20
CN105612162B (zh) 2018-08-21
JP6419800B2 (ja) 2018-11-07
EP3055315B1 (en) 2018-07-25
CN108929336A (zh) 2018-12-04
RU2703273C2 (ru) 2019-10-16
HK1220202A1 (zh) 2017-04-28
SI3055315T1 (sl) 2018-11-30
HRP20181596T1 (hr) 2018-12-14
RU2016115487A (ru) 2017-11-16
LT3055315T (lt) 2018-10-25
CA2926830C (en) 2023-08-01
EP3415519A1 (en) 2018-12-19
JP2019023217A (ja) 2019-02-14
PL3055315T3 (pl) 2018-12-31
KR102361108B1 (ko) 2022-02-10
RS58047B1 (sr) 2019-02-28
KR20160068898A (ko) 2016-06-15
WO2015052226A1 (en) 2015-04-16
ES2690355T3 (es) 2018-11-20
EP3055315A1 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
MX367420B (es) Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
PH12014501914A1 (en) Anti sez6 antibodies and methods of use
SG10201806867VA (en) Dll3 modulators and methods of use
MX2021000007A (es) Formulaciones de enzalutamida.
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
MX2016002574A (es) Nuevos moduladores del homologo 6 (sez6) y metodos de uso.
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
PH12016500967A1 (en) Functionalised and substituted indoles as anti-cancer agents
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
IN2013MU03641A (es)
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
EA026371B8 (ru) Индолкарбонитрилы в качестве модуляторов рецептора андрогенов
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
UA114811C2 (uk) Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу
IN2013CH00453A (es)
IN2013CH05769A (es)
IN2013CH05171A (es)

Legal Events

Date Code Title Description
FG Grant or registration